Compare Gilead Sciences, Inc. (GILD) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while Vanguard Total Stock Market Index Fund ETF trades at $370.5. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VTI | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $374.36 |
52-Week Low | $108.22 | $305.74 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VTI trades at $371.26 with minimal daily movement (+0.03%), maintaining a bullish technical stance supported by moving averages. The ETF's broad exposure to the entire U.S. stock market provides diversification across 3,400+ companies. Recent news highlights strong long-term performance potential, with historical returns averaging nearly 10% annually over 25 years.
The outlook remains positive for long-term investors seeking comprehensive U.S. market exposure at minimal cost (0.03% expense ratio). Key risks include market-wide volatility and economic downturns, though VTI has historically weathered recessions. Analyst sentiment favors VTI for its simplicity and cost-effectiveness in building diversified portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
